mizoribine has been researched along with valsartan in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chihara, Y; Fujimori, T; Iidaka, K; Inada, H; Ishimitsu, T; Matsuoka, H; Ogihara, T; Ono, H; Ono, Y; Rakugi, H; Ueda, Y | 1 |
Nakanishi, K; Nozu, K; Okamoto, M; Yokoyama, N; Yoshikawa, N | 1 |
3 other study(ies) available for mizoribine and valsartan
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Angiotensin type 1 receptor blocker reduced proteinuria in patients of focal glomerular sclerosis].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diet, Protein-Restricted; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Losartan; Male; Methylprednisolone; Middle Aged; Prednisolone; Proteinuria; Remission Induction; Ribonucleosides; Tetrazoles; Valine; Valsartan | 2004 |
Crescentic IgA nephropathy in a child: Effect of a new combination therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Child; Drug Therapy, Combination; Glomerulonephritis, IGA; Humans; Lisinopril; Male; Prednisolone; Ribonucleosides; Valsartan | 2017 |